A
growing number of current and recovered COVID-19 patients in India are
contracting a deadly and rare fungal infection, doctors told AFP Monday
as the vast nation battles to contain a massive outbreak of virus cases.
On
Monday, India reported 370,000 coronavirus infections, bringing the
total to 22.7 million cases, with more than 3,700 new deaths.
Experts said the actual number of cases and fatalities could be much higher.
Mucormycosis,
dubbed “black fungus” by doctors in India, is usually most aggressive
in patients whose immune systems are weakened by other infections.
Medical
experts said they had seen a rise in cases in India in recent weeks,
while the health ministry on Sunday released an advisory on how to treat
the infection.
“The cases of mucormycosis infection in Covid-19
patients post-recovery is nearly four to five times than those reported
before the pandemic,” Ahmedabad-based infectious diseases specialist
Atul Patel, a member of the state’s COVID-19 taskforce, told AFP.
In
the western state of Maharashtra, home to India’s financial hub Mumbai,
up to 300 cases have been detected, said Khusrav Bajan, a consultant at
Mumbai’s P.D. Hinduja National Hospital and a member of the state’s
COVID-19 Task Force.
At least another 300 cases have been
reported so far in four cities in Gujarat, including its largest
Ahmedabad, according to data from state-run hospitals.
The
western state ordered government hospitals to set up separate treatment
wards for patients infected with “black fungus” amid the rise in cases.
“Mucormycosis
— if uncared for — may turn fatal,” the Indian Council for Medical
Research (ICMR), the scientific agency leading the government’s
response, said in a treatment chart released on Twitter.
COVID-19
sufferers are more susceptible to contracting the fungal infection.
This includes those with uncontrolled diabetes, those who used steroids
during their virus treatment, and those who had prolonged stays in
hospital ICUs, the ICMR added.
Treatment involves surgically removing all dead and infected tissue and administering a course of anti-fungal therapy.
But
Yogesh Dabholkar, an ear, nose and throat specialist at Mumbai’s DY
Patil Hospital, told AFP that the drugs used to treat those infected
with the fungus are very expensive.
One of the treatment drugs was also running short in government hospitals due to the sudden spike, he added.
“The mortality rate is very high… Even the few that recover, only recover with extensive and aggressive surgery,” Bajan said.
“This
is a fast-moving infection. It can grow within two weeks… It’s a
Catch-22, coming out of a virus and getting into a fungal infection.
It’s really bad.”
Hope Singapore has not imported the black fungus disease from India yet.
LIPS